An RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond

Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.

By Michael Gibney • Nov. 26, 2024

A biotech’s difficult journey to bring a new kind of Parkinson’s drug to patients

A series of executive turnovers at Gain Therapeutics this year precedes important early-stage Parkinson’s results that could change how the disease is treated.

By Michael Gibney • Aug. 13, 2024

A biotech dousing ‘fires’ in the brain that plagued a bestselling author

Arialys Therapeutics is developing a precision medicine treatment for a rare autoimmune encephalitis that mimics psychosis.

By Alexandra Pecci • Aug. 7, 2024

A new biotech tackling IBD joins a race against Lilly and Gilead for a promising pill

Ensho Therapeutics just launched but is already generating buzz with its phase 2-ready clinical program for inflammatory bowel disease.

By Alexandra Pecci • July 17, 2024

Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders

Mid-stage data from the company’s lead candidate in Parkinson’s is expected later this year and could tee up an IPO.

By Meagan Parrish • July 15, 2024

Protein power: a biotech mining viruses to fight disease

Flagship Pioneering-backed Prologue Medicine is harnessing the evolutionary tactics of viral proteins to systematically find new drugs.

By Kelly Bilodeau • July 1, 2024

Regenerative cell therapy biotech uses IPO to blast into human trials

Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.

By Amy Baxter • June 5, 2024

Mythic Therapeutics aims to overcome one of ADC’s long-standing challenges

By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.

By Alexandra Pecci • May 30, 2024

Traditional gene therapies are uber-niche. Ocugen hopes to change that.

The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.

By Alexandra Pecci • April 15, 2024

What’s old is new: The revival of a one-time radiotherapy cancer treatment

TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.

By Amy Baxter • April 10, 2024

GSK has the U.S. shingles vaccine market cornered. A jab with fewer side effects could change that.

Curevo Vaccine is readying a phase 3 trial for a candidate it believes could have an edge over GSK’s blockbuster Shingrix.

By Alexandra Pecci • March 19, 2024

Black Diamond looks to outwit cancer mutations

Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

By Kelly Bilodeau • March 4, 2024

Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care

With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.  

By Alexandra Pecci • Feb. 6, 2024

One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery

4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.

By Michael Gibney • Jan. 10, 2024

This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain

Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.

By Michael Gibney • Dec. 19, 2023

A biotech tackles drug discovery with transcription factor know-how

Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

By Michael Gibney • Nov. 15, 2023

A new delivery method muscling its way into the RNA space

With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

By Kelly Bilodeau • Nov. 8, 2023

Cidara’s J&J-partnered immunotherapy could target flu and cancer

On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

By Alexandra Pecci • Oct. 26, 2023

An ‘inverse vaccine’ takes aim at autoimmune diseases

Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

By Kelly Bilodeau • Oct. 23, 2023

To close the pediatric innovation gap, this biotech has to think differently

Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

By Alexandra Pecci • Oct. 11, 2023

A biotech ‘tuning’ the genome for a potentially safer gene therapy

Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

By Kelly Bilodeau • Oct. 9, 2023

Immuneering takes aim at cancer’s ‘superhighway’

After dropping its neuroscience program earlier this year, the clinical-stage oncology company is doubling down on a candidate targeting the MAPK pathway.

By Kelly Bilodeau • Sept. 11, 2023

‘We need to do better:’ A biotech CEO on standing apart from the crowd

The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

By Michael Gibney • Aug. 29, 2023

Brii Biosciences aims to come up big where Sage and Biogen fell short

The depression space recently got a stinging FDA rebuke — but Brii thinks it can break through with improved formulations.

By Kelly Bilodeau • Aug. 21, 2023

Why AbbVie’s former president has high hopes for this Flagship-backed biotech

The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

By Karissa Waddick • Aug. 7, 2023